Antibe Therapeutics Inc(Pre-Merger) ATBPF

RJ Initates Coverage... G&M

[ace1mccoy]

* Raymond James analyst David Novak initiated coverage of Antibe Therapeutics Inc. (ATE-T) with an “outperform” rating and $7 target. The current average is $17.59.

“We believe ATE shares are well-positioned for a significant market re-rating over the next 12-months and thus view the company as an attractive investment opportunity for risk-tolerant investors,” he said.

[MrMugsy]

And the Raymond James conference call is next Tuesday !!!

[123ABC]

OMG target is what the SP was in February!!!!!...lol

[Inthepez]

When is your tantrum going to be over? 

[Forestview]

I'm hoping it hits $7 so that 123 and PantyhoseUp and others sell and make their $12 profit and then go away.  Your repeated comments are exhausting.

[123ABC]

Use the ignore button my man

[Pandora]

Yeah, we're already up over 4% today. Did we do something wrong?

[Notthatbright]

You are only UP if you bought yesterday, otherwise we are DOWN a bit less.

[IrishCanuck]

Glass is half empty kind of person huh? Lots of us are in the black still, hence we are not sweating

[Notthatbright]

yup, till it spills over the rim.

[YukonJezza]

Ahem!!!! The SP is half what it was 5 months ago. Plus management keeps diluting what's in the glass.

[IrishCanuck]

And it's 4x what it was 4 years ago including all that dilution, what's your point? 

[YukonJezza]

that is true irishcanuck. ATE took a real nosedive 4 years ago. And Ates current SP is below the IPO price 8 years ago I believe. At least we are up 4% today eh?